Phospho-NF kappaB p100/p52 (Ser870) Antibody - #AF3374
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# AF3374, RRID:AB_2834805.
展开/折叠
CVID10; DNA binding factor KBF2; H2TF1; Lymphocyte translocation chromosome 10 protein; LYT 10; NF kB2; NFKB p52/p100 subunit; Nuclear factor Kappa B subunit 2; Nuclear factor of kappa light polypeptide gene enhancer in B cells 2 (p49/p100); Nuclear factor of kappa light polypeptide gene enhancer in B cells 2; Oncogene Lyt 10; p100; Transcription factor NFKB2;
抗原和靶标
- Q00653 NFKB2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MESCYNPGLDGIIEYDDFKLNSSIVEPKEPAPETADGPYLVIVEQPKQRGFRFRYGCEGPSHGGLPGASSEKGRKTYPTVKICNYEGPAKIEVDLVTHSDPPRAHAHSLVGKQCSELGICAVSVGPKDMTAQFNNLGVLHVTKKNMMGTMIQKLQRQRLRSRPQGLTEAEQRELEQEAKELKKVMDLSIVRLRFSAFLRASDGSFSLPLKPVISQPIHDSKSPGASNLKISRMDKTAGSVRGGDEVYLLCDKVQKDDIEVRFYEDDENGWQAFGDFSPTDVHKQYAIVFRTPPYHKMKIERPVTVFLQLKRKRGGDVSDSKQFTYYPLVEDKEEVQRKRRKALPTFSQPFGGGSHMGGGSGGAAGGYGGAGGGGSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSRDSGEEAAEPSAPSRTPQCEPQAPEMLQRAREYNARLFGLAQRSARALLDYGVTADARALLAGQRHLLTAQDENGDTPLHLAIIHGQTSVIEQIVYVIHHAQDLGVVNLTNHLHQTPLHLAVITGQTSVVSFLLRVGADPALLDRHGDSAMHLALRAGAGAPELLRALLQSGAPAVPQLLHMPDFEGLYPVHLAVRARSPECLDLLVDSGAEVEATERQGGRTALHLATEMEELGLVTHLVTKLRANVNARTFAGNTPLHLAAGLGYPTLTRLLLKAGADIHAENEEPLCPLPSPPTSDSDSDSEGPEKDTRSSFRGHTPLDLTCSTKVKTLLLNAAQNTMEPPLTPPSPAGPGLSLGDTALQNLEQLLDGPEAQGSWAELAERLGLRSLVDTYRQTTSPSGSLLRSYELAGGDLAGLLEALSDMGLEEGVRLLRGPETRDKLPSTAEVKEDSAYGSQSVEQEAEKLGPPPEPPGGLCHGHPQPQVH
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - Q00653 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
K19 | Sumoylation | Uniprot | |
S22 | Phosphorylation | Uniprot | |
S23 | Phosphorylation | Uniprot | |
K28 | Ubiquitination | Uniprot | |
K47 | Ubiquitination | Uniprot | |
Y55 | Phosphorylation | Uniprot | |
K72 | Ubiquitination | Uniprot | |
K90 | Sumoylation | Uniprot | |
T97 | Phosphorylation | Uniprot | |
S99 | Phosphorylation | O15111 (CHUK) | Uniprot |
S108 | Phosphorylation | O15111 (CHUK) | Uniprot |
K112 | Ubiquitination | Uniprot | |
S115 | Phosphorylation | O15111 (CHUK) | Uniprot |
S123 | Phosphorylation | O15111 (CHUK) | Uniprot |
K143 | Ubiquitination | Uniprot | |
K144 | Ubiquitination | Uniprot | |
K153 | Ubiquitination | Uniprot | |
S161 | Phosphorylation | Uniprot | |
T167 | Phosphorylation | Uniprot | |
K179 | Ubiquitination | Uniprot | |
S204 | Phosphorylation | Uniprot | |
S222 | Phosphorylation | P49841 (GSK3B) | Uniprot |
K229 | Ubiquitination | Uniprot | |
K235 | Ubiquitination | Uniprot | |
K252 | Ubiquitination | Uniprot | |
S277 | Phosphorylation | Uniprot | |
Y285 | Phosphorylation | Uniprot | |
K298 | Sumoylation | Uniprot | |
K321 | Ubiquitination | Uniprot | |
Y325 | Phosphorylation | Uniprot | |
Y326 | Phosphorylation | Uniprot | |
K332 | Ubiquitination | Uniprot | |
T429 | Phosphorylation | Uniprot | |
T651 | Phosphorylation | Uniprot | |
T655 | Phosphorylation | Uniprot | |
T682 | Phosphorylation | Uniprot | |
K689 | Sumoylation | Uniprot | |
S707 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S711 | Phosphorylation | P49841 (GSK3B) | Uniprot |
S713 | Phosphorylation | Uniprot | |
S715 | Phosphorylation | Uniprot | |
S717 | Phosphorylation | Uniprot | |
S727 | Phosphorylation | Uniprot | |
S739 | Phosphorylation | Uniprot | |
K741 | Ubiquitination | Uniprot | |
K743 | Ubiquitination | Uniprot | |
S762 | Phosphorylation | Uniprot | |
S802 | Phosphorylation | Uniprot | |
S812 | Phosphorylation | Uniprot | |
K855 | Ubiquitination | Uniprot | |
S858 | Phosphorylation | Uniprot | |
T859 | Phosphorylation | Uniprot | |
K863 | Sumoylation | Uniprot | |
S866 | Phosphorylation | Q99558 (MAP3K14) | Uniprot |
Y868 | Phosphorylation | Uniprot | |
S870 | Phosphorylation | Q99558 (MAP3K14) | Uniprot |
S872 | Phosphorylation | O15111 (CHUK) | Uniprot |
研究背景
NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.
While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p52 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
Subsequent to MAP3K14-dependent serine phosphorylation, p100 polyubiquitination occurs then triggering its proteasome-dependent processing.
Constitutive processing is tightly suppressed by its C-terminal processing inhibitory domain, named PID, which contains the death domain.
Nucleus. Cytoplasm.
Note: Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).
Component of the NF-kappa-B RelB-p52 complex. Homodimer; component of the NF-kappa-B p52-p52 complex. Component of the NF-kappa-B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel complex. NFKB2/p52 interacts with NFKBIE. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Directly interacts with MEN1.
The C-terminus of p100 might be involved in cytoplasmic retention, inhibition of DNA-binding by p52 homodimers, and/or transcription activation.
The glycine-rich region (GRR) appears to be a critical element in the generation of p52.
研究领域
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway. (View pathway)
· Human Diseases > Infectious diseases: Bacterial > Legionellosis.
· Human Diseases > Infectious diseases: Viral > HTLV-I infection.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Viral carcinogenesis.
· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)
· Organismal Systems > Development > Osteoclast differentiation. (View pathway)
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.